{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:18:06Z","timestamp":1791429486547,"version":"4.3.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>A MASCC\/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians, which concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the management of oral manifestations of chronic graft-versus-host-disease (cGVHD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC\/ISOO. The information is presented in the form of succinct bullets and table to generate a short manual about the best standard of care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The treatment goals in oral cGVHD are to relieve pain and xerostomia, improve oral function, prevent secondary infection, prevent deterioration of the dentition, and detect malignant transformation as early as possible. The prevention and treatment measures for oral mucosal lesions, hypofunction of the salivary glands, and sclerodermatous changes in the oral and perioral tissues are detailed, as well as the possible complications and side effects of these interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients post allogeneic hematopoietic cell transplantations, with cGVHD manifest in the oral and perioral tissues, should be regularly monitored and treated as needed by an oral care practitioner. This CPS provides the clinician with practical tools for examining, preventing, and treating the various sequalae that may affect the oral cavity in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08686-x","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:01:45Z","timestamp":1721869305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MASCC\/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-6529","authenticated-orcid":false,"given":"Yehuda","family":"Zadik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Raber-Durlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Majorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Laheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bardellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Elad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"3","key":"8686_CR1","doi-asserted-by":"publisher","first-page":"903154","DOI":"10.3389\/froh.2022.903154.PMID:35719318;PMCID:PMC9205403","volume":"20","author":"D Dean","year":"2022","unstructured":"Dean D, Sroussi H (2022) Oral Chronic Graft-Versus-Host Disease. Front Oral Health 20(3):903154. https:\/\/doi.org\/10.3389\/froh.2022.903154.PMID:35719318;PMCID:PMC9205403","journal-title":"Front Oral Health"},{"issue":"1","key":"8686_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/idj.12584","volume":"71","author":"S Elad","year":"2021","unstructured":"Elad S, Aljitawi O, Zadik Y (2021) Oral Graft-Versus-Host Disease: A Pictorial Review and a Guide for Dental Practitioners. Int Dent J. 71(1):9\u201320. https:\/\/doi.org\/10.1111\/idj.12584","journal-title":"Int Dent J."},{"issue":"11","key":"8686_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.adaj.2020.08.001","volume":"151","author":"TM Haverman","year":"2020","unstructured":"Haverman TM, Raber-Durlacher JE, Raghoebar II et al (2020) Oral chronic graft-versus-host disease: What the general dental practitioner needs to know. J Am Dent Assoc 151(11):846\u2013856. https:\/\/doi.org\/10.1016\/j.adaj.2020.08.001. (PMID: 33121606)","journal-title":"J Am Dent Assoc"},{"issue":"7","key":"8686_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","volume":"21","author":"PA Carpenter","year":"2015","unstructured":"Carpenter PA, Kitko CL, Elad S et al (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 21(7):1167\u20131187. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.024","journal-title":"Biol Blood Marrow Transplant."},{"key":"8686_CR5","doi-asserted-by":"publisher","unstructured":"Raber-Durlacher JE, Treister NS, Zadik Y et al (2024) MASCC\/ISOO clinical practice statement: the risk of secondary oral cancer following hematopoietic cell transplantation. Support Care Cancer https:\/\/doi.org\/10.1007\/s00520-024-08685-y","DOI":"10.1007\/s00520-024-08685-y"},{"key":"8686_CR6","doi-asserted-by":"publisher","unstructured":"Einarsdottir MJ, Bankvall M, Robledo-Sierra J, et al (2023) Topical clobetasol treatment for oral lichen planus can cause adrenal insufficiency. Oral Dis https:\/\/doi.org\/10.1111\/odi.14588","DOI":"10.1111\/odi.14588"},{"issue":"8","key":"8686_CR7","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.bbmt.2018.02.022","volume":"24","author":"S Elad","year":"2018","unstructured":"Elad S, Zinchuk K, Li S et al (2018) Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24(8):1748\u20131753. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.022. (PMID: 29501781)","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"8686_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.oooo.2019.07.024","volume":"128","author":"PJ Fantozzi","year":"2019","unstructured":"Fantozzi PJ, Treister N, Shekar R et al (2019) Intralesional triamcinolone acetonide therapy for inflammatory oral ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol 128(5):485\u2013490. https:\/\/doi.org\/10.1016\/j.oooo.2019.07.024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"8686_CR9","unstructured":"Mathes BM, Alguire PC (2023) Intralesional corticosteroid injection. UpToDate. 2021. Topic 5568 Version 15.0. Accessed August 30, 2023. Available at: https:\/\/www.uptodate.com\/contents\/intralesional-corticosteroid-injection?search=intralesional%20corticosteroid%20injection&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H205304705"},{"issue":"19","key":"8686_CR10","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV et al (2020) Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\/ISOO). MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126(19):4423\u20134431. https:\/\/doi.org\/10.1002\/cncr.33100","journal-title":"Cancer"},{"issue":"2","key":"8686_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00520-016-3401-1","volume":"25","author":"JB Epstein","year":"2017","unstructured":"Epstein JB, Raber-Durlacher JE, Lill M et al (2017) Photobiomodulation therapy in the management of chronic oral graft-versus-host disease. Support Care Cancer 25(2):357\u2013364. https:\/\/doi.org\/10.1007\/s00520-016-3401-1. (Epub 2016 Sep 21 PMID: 27655559)","journal-title":"Support Care Cancer"},{"issue":"8","key":"8686_CR12","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1007\/s00520-021-05997-1","volume":"29","author":"O Finfter","year":"2021","unstructured":"Finfter O, Avni B, Grisariu S et al (2021) Photobiomodulation (low-level laser) therapy for immediate pain relief of persistent oral ulcers in chronic graft-versus-host disease. Support Care Cancer 29(8):4529\u20134534. https:\/\/doi.org\/10.1007\/s00520-021-05997-1","journal-title":"Support Care Cancer"},{"key":"8686_CR13","doi-asserted-by":"publisher","unstructured":"Hong C, Jensen SB, Vissink A et al (2024) MASCC\/ISOO clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer https:\/\/doi.org\/10.1007\/s00520-024-08688-9","DOI":"10.1007\/s00520-024-08688-9"},{"issue":"6","key":"8686_CR14","doi-asserted-by":"publisher","first-page":"480.e1","DOI":"10.1016\/j.jtct.2021.02.020","volume":"27","author":"M Mousavian","year":"2021","unstructured":"Mousavian M, Sroussi H, Villa A et al (2021) Use of Prescription Sialagogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease. Transplant Cell Ther 27(6):480.e1-480.e5. https:\/\/doi.org\/10.1016\/j.jtct.2021.02.020. (Epub 2021 Feb 25 PMID: 33846113)","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"8686_CR15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1111\/odi.13152","volume":"25","author":"DJ Aframian","year":"2019","unstructured":"Aframian DJ, Baaton S, Mazor S et al (2019) Improvement of dry mouth following intraductal irrigation of salivary glands. Oral Dis 25(7):1735\u20131743. https:\/\/doi.org\/10.1111\/odi.13152. (Epub 2019 Aug 1 PMID: 31278807)","journal-title":"Oral Dis"},{"issue":"3","key":"8686_CR16","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.4317\/medoral.19429.PMID:24121920;PMCID:PMC4048107","volume":"19","author":"Y Zadik","year":"2014","unstructured":"Zadik Y, Zeevi I, Luboshitz-Shon N et al (2014) Safety and efficacy of an intra-oral electrostimulator for the relief of dry mouth in patients with chronic graft versus host disease: Case series. Med Oral Patol Oral Cir Bucal 19(3):e212\u2013e219. https:\/\/doi.org\/10.4317\/medoral.19429.PMID:24121920;PMCID:PMC4048107","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"10","key":"8686_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.adaj.2018.07.002","volume":"149","author":"RL Slayton","year":"2018","unstructured":"Slayton RL, Urquhart O, Araujo MWB et al (2018) Evidence-based clinical practice guideline on nonrestorative treatments for carious lesions: A report from the American Dental Association. J Am Dent Assoc 149(10):837-849.e19. https:\/\/doi.org\/10.1016\/j.adaj.2018.07.002. (PMID: 30261951)","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"8686_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00520-014-2378-x","volume":"23","author":"S Elad","year":"2015","unstructured":"Elad S, Raber-Durlacher JE, Brennan MT et al (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23(1):223\u201336. https:\/\/doi.org\/10.1007\/s00520-014-2378-x","journal-title":"Support Care Cancer"},{"issue":"6","key":"8686_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s12185-018-2520-5","volume":"108","author":"A Piccin","year":"2018","unstructured":"Piccin A, Tagnin M, Vecchiato C et al (2018) Graft-versus-host disease (GvHD) of the tongue and of the oral cavity: a large retrospective study. Int J Hematol 108(6):615\u2013621. https:\/\/doi.org\/10.1007\/s12185-018-2520-5. (Epub 2018 Aug 24 PMID: 30144000)","journal-title":"Int J Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08686-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08686-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08686-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:09:42Z","timestamp":1723612182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08686-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8686"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08686-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"A. Majorana, E. Bardellini, and N. Blijlevens reported no relevant financial or non-financial interests to disclose.Y. Zadik was a coinvestigator for the study NCT00887263 sponsored by Dr. Falk Pharma GmbH. Y. Zadik received personal fees from SBRBio, and equipment and personal fees for lectures from Erika Carmel and Taro Pharmaceutical Industries.J.E. Raber-Durlacher and A.M.G.A. Laheij received in-kind support from Thor Photomedicine Inc.J.B. Epstein is a consultant for Galera Therapeutics, Janssen Biopharmaceuticals, Nestle Healthcare, Tosk Inc., and a consultant and has funded research from SaNOtize Research and Development Corp. J.B. Epstein is associated Editor-in-Chief for Supportive Care in Cancer.S. Elad is the medical consultant for the study NCT00887263 sponsored by Dr. Falk Pharma GmbH.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MASCC\/ISOO OCSG Statements have been developed to facilitate the expert-opinion based management of oral complications of cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. The Statement authors and the MASCC\/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"546"}}